Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer
Despite the advances in supportive care for cancer patients, they often develop such a serious complication of chemotherapy as febrile neutropenia. This disorder is the main cause of reduced treatment efficacy because of the lower doses of cytostatics or even withdrawal of myelosuppressive therapy i...
Saved in:
| Main Authors: | L. G. Babicheva, S. O. Podvyaznikov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-11-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/675 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01) -
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
by: Advani S, et al.
Published: (2010-01-01) -
Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs?
by: G. A. Gromova
Published: (2023-08-01) -
Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01) -
Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation
by: M. V. Zhuravleva, et al.
Published: (2024-02-01)